Atorvastatin in Moderate Active Crohns Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00454545|
Recruitment Status : Completed
First Posted : March 30, 2007
Last Update Posted : October 22, 2007
|Condition or disease||Intervention/treatment||Phase|
|Crohns Disease||Drug: Atorvastatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||October 2006|
|Actual Study Completion Date :||October 2007|
- Inflammatory markers in plasma before and after treatment.
- Change in clinical activity index and mucosal inflammation after treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00454545
|Department of Medicine, Division of Gastroenterology and Hepatology|
|Malmö, Sweden, 20502 Malmö|
|Principal Investigator:||Olof Grip, MD, PhD||Malmo University Hospital, Region Skåne|
|Study Chair:||Anders Bredberg, MD, PhD||Malmo University Hospital, Region Skåne|
|Study Chair:||Gunnel Bredberg, MD, PhD||Malmo University Hospital, Region Skåne|